首页> 外文期刊>British journal of ophthalmology >Visual acuity and central retinal thickness: Fulfilment of retreatment criteria for recurrent neovascular AMD in routine clinical care
【24h】

Visual acuity and central retinal thickness: Fulfilment of retreatment criteria for recurrent neovascular AMD in routine clinical care

机译:视力和视网膜中央厚度:常规临床护理中复发性血管新生AMD的再治疗标准

获取原文
获取原文并翻译 | 示例
       

摘要

Background: To evaluate the fulfilment of retreatment criteria in recurrent neovascular age-related macular degeneration (nAMD) for a pro-re-nata treatment regime with ranibizumab in routine clinical care.Methods: Data from patients with treatment-naive nAMD were analysed retrospectively. As an 'upload', all patients had received three-monthly intravitreal ranibizumab injections in a university eye hospital and were then seen by ophthalmologists in private practice who referred them back in case of recurrence. Recurrence was defined as a decrease of visual acuity (VA) of one line or more (functional retreatment criteria), a central retinal thickness (CRT) increase of at least 100 mm upon Optical Coherence Tomography (OCT) examination (morphological retreatment criteria) or a new macular haemorrhage (clinical retreatment criteria).Results: We included 92 patients (36 men and 56 women). The mean VA before retreatment of a recurrence was -0.63±0.33 logMAR and improved significantly (p<0.001) by 0.10±0.16 logMAR to -0.53±0.28 logMAR thereafter. Mean CRT before retreatment was 278.07±87.56 mm and decreased significantly (p<0.001) by 71.22±106.93 to 206.85±60.30 mm. Evaluation of the fulfilment of retreatment criteria revealed functional retreatment criteria in 82.6% of patients. However, upon re-evaluation of VA using Early Treatment Diabetic Retinopathy Study (ETDRS) charts in the treatment centre, mean decrease of VA was 10 letters as compared with the end of upload therapy. All patients presented an increased CRT when treated for recurrence of nAMD (mean increase 69.47 mm), but the morphological retreatment criteria (CRT increase of 100 mm or more) were fulfilled in only 44.4% of patients upon Spectral Domain OCT (SD-OCT) evaluation in the treatment centre.Conclusions: In a routine clinical care, evaluation of VA using ETDRS charts seems to be more sensitive than Snellen VA testing. Quantitative OCT-based retreatment criteria (eg, increase of CRT of 100 mm or more) appear to be not sensitive enough in a clinical setting with referring ophthalmologists.
机译:背景:为评估兰尼单抗在常规临床护理中的前再治疗方案,在复发性新血管性年龄相关性黄斑变性(nAMD)中是否符合再治疗标准。方法:回顾性分析未接受过治疗的nAMD患者的数据。作为“上载”,所有患者在一家大学眼科医院接受了三个月一次的玻璃体内兰尼单抗注射,然后由私人执业的眼科医生看到,一旦复发,将其转回。复发的定义是视力(VA)降低一行或更多(功能再治疗标准),视网膜中央厚度(CRT)在光学相干断层扫描(OCT)检查中至少增加100 mm(形态再治疗标准),或结果:我们纳入了92例患者(36例男性和56例女性)。复发再治疗前的平均VA为-0.63±0.33 logMAR,并由0.10±0.16 logMAR显着提高(p <0.001)至其后的-0.53±0.28 logMAR。再治疗前的平均CRT为278.07±87.56 mm,显着降低(p <0.001)71.22±106.93至206.85±60.30 mm。评估再治疗标准的实现情况后,在82.6%的患者中发现了功能再治疗标准。但是,在治疗中心使用早期糖尿病性视网膜病变研究(ETDRS)图表对VA进行重新评估后,与上载疗法结束相比,VA的平均下降为10个字母。所有患者接受nAMD复发治疗时CRT均升高(平均增加69.47 mm),但通过光谱域OCT(SD-OCT)的形态学再治疗标准(CRT增加100 mm或更高)仅达到44.4%结论:在常规临床护理中,使用ETDRS图评估VA似乎比Snellen VA测试更为敏感。基于OCT的定量再治疗标准(例如,CRT增加100 mm或更多)似乎在临床环境中对眼科医生没有足够的敏感性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号